Supplementary Figure 5 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

Authors:

Abstract
Supplementary figure 5 shows baseline versus end-of-treatment tumor mutation status among those who achieved a defined clinical benefit on treatment.